To achieve capital growth and income from a portfolio of predominantly UK equities
Name | % Net Assets |
---|---|
Royal Dutch Shell PLC | 8.7% |
GlaxoSmithKline PLC | 6.3% |
Vodafone Group PLC | 5.9% |
BG Group PLC | 4.4% |
AstraZeneca PLC | 4.4% |
British American Tobacco PLC | 4.0% |
Unilever PLC | 3.1% |
Cadbury PLC | 2.8% |
BP PLC | 2.8% |
Centrica PLC | 2.7% |
Key | % Net Assets |
---|---|
Royal Dutch Shell PLC | 8.7% |
GlaxoSmithKline PLC | 6.3% |
Vodafone Group PLC | 5.9% |
BG Group PLC | 4.4% |
Other | 74.7% |
Date | 02-Oct-2023 |
---|---|
NAV | 313.04p |
Currency | GBP |
Change | -3.66p |
% | -1.16% |
YTD change | 313.04p |
YTD % | n/a |
Fund Inception | 01/05/1985 |
---|---|
Fund Manager | Glen Pratt |
TER | 1.04 (30-Dec-2011) |
Minimum Investment | |
---|---|
Initial | n/a |
Additional | n/a |
Savings | n/a |
Charges | |
---|---|
Initial | 4.00% |
Annual Mang't | 1.00% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.02 |
Sharpe ratio | 0.06 |
You are here: research